Consequently, TSPO has been identified as an in vivo biomarker of neuroinflammation detectable via positron emission tomography (PET) and a potential target for the treatment of a range of neurodegenerative diseases, including Alzheimer's disease 3-5. This evidence concerns the gene TSPO and early-onset autosomal dominant Alzheimer disease.